TOP > 外国特許検索 > PROPHYLACTIC OR THERAPEUTIC FOR GM1 GANGLIOSIDOSIS, AND COMPOSITION FOR PREVENTING OR TREATING GM1 GANGLIOSIDOSIS

PROPHYLACTIC OR THERAPEUTIC FOR GM1 GANGLIOSIDOSIS, AND COMPOSITION FOR PREVENTING OR TREATING GM1 GANGLIOSIDOSIS NEW

外国特許コード F190009930
整理番号 (S2018-0245-N0)
掲載日 2019年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP048411
国際公開番号 WO 2019131989
国際出願日 平成30年12月28日(2018.12.28)
国際公開日 令和元年7月4日(2019.7.4)
優先権データ
  • 特願2017-254888 (2017.12.28) JP
発明の名称 (英語) PROPHYLACTIC OR THERAPEUTIC FOR GM1 GANGLIOSIDOSIS, AND COMPOSITION FOR PREVENTING OR TREATING GM1 GANGLIOSIDOSIS NEW
発明の概要(英語) Provided is a prophylactic or therapeutic for GM1 gangliosidosis, characterized by comprising, as an active ingredient, at least one selected from the group consisting of amodiaquine, acacetin, sulfamerazine, ungerine, amiodarone, sertindole, delcorine, perphenazine, althiazide, diethylstilbestrol, thiethylperazine, harmol, skimmianine, succinylsulfathiazole, phillalbine, canavanine, harmaline, trihexyphenidyl, fluoxetine, lovastatin, haloperidol, prenylamine・lactate, bromperidol, convolvamine, and miglustat. Also provided are pharmaceutically acceptable salts or solvates of said prophylactic or therapeutic.
従来技術、競合技術の概要(英語) BACKGROUND ART
GM1 Ganglioside is, a kind of glycolipids, involved in cell signaling molecules. Diseases involving such as GM1, GM1 gangliosidosis known.
GM1 Gangliosidosis and lysosomes is one of the disease 1, ganglioside GM1 participates in the hydrolysis of the deficiency, by an abnormality, the nervous system (brain) particularly GM1 to accumulate the innate in metabolism. GM1 Gangliosidosis is, by the clinical course and the onset time, an infant type, juvenile, adult classified into. In particular the age of 3-6 months for the development of the infant-delay can be seen, most of the 1 year old until the affected infant, such as by dividing the stiffness of the brain as indicated by a neurological disorder severity, age of death of the normal 3-4.
GM1 Gangliosidosis in the development of therapeutic agents to, for example, in Non-Patent Document 1, as a prophylaxis GM1 gangliosidosis, caspase inhibitors in the Z-YVAD-FMK has been proposed.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
  • 発明者(英語)
  • ERA Takumi
  • KAJIHARA Ryutaro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接ご連絡ください。

PAGE TOP

close
close
close
close
close
close